Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study
Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine. Objective: To compare the real-world effectiveness of erenumab and non-specific oral migraine preventive medication (OMPM) o...
Guardado en:
Autores principales: | Stewart J Tepper, Juanzhi Fang, Lujia Zhou, Pamela Vo, Ahmad Abdrabboh, Mrudula Glassberg, Matias Ferraris |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c34ea09e7919453a84bd75c1b089350f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Preventive treatment in migraine and the new US guidelines
por: Estemalik E, et al.
Publicado: (2013) -
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
por: Andreas Straube, et al.
Publicado: (2021) -
Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus
por: Andria Tziakouri, et al.
Publicado: (2021) -
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
por: Sara Bottiroli, et al.
Publicado: (2021) -
Prophylaxis of migraine: general principles and patient acceptance
por: Domenico D’Amico, et al.
Publicado: (2008)